Other, Other, Publications UPGRADE: Phase 1 Trial of the NaPi2b‑Directed Dolaflexin Antibody‑Drug Conjugate UpRi in Combination With Carboplatin in Patients With Platinum‑Sensitive Ovarian Cancer (PSOC)
Other, Other, Publications UPLIFT: Results from the Phase 2 Trial of Upifitamab Rilsodotin (UpRi; XMT-1536), a NaPi2b-Directed Dolaflexin ADC in Platinum-Resistant Ovarian Cancer
Other, Other, Publications UPGRADE-A: Phase 1 Expansion Trial of the NaPi2b-Directed Antibody Drug Conjugate Upifitamab Rilsodotin in Combination With Carboplatin in Patients With High-Grade Serous Ovarian Cancer
Other, Other, Publications Correlating Expression of NaPi2b and Folate Receptor Alpha (FRα) in High‑Grade Serous Ovarian Cancer (HGSOC)
Other, Other, Publications UP‑NEXT (GOG‑3049/ENGOT‑ov71‑NSGO‑CTU): A Study of Upifitamab Rilsodotin (UpRi), a NaPi2b‑directed Antibody‑Drug Conjugate in Platinum‑Sensitive Recurrent Ovarian Cancer
Other, Other, Publications Advances in Ovarian Cancer Care and Unmet Treatment Needs for Patients with Platinum Resistance
Other, Other, Publications NaPi2b Expression in High-Grade Serous Ovarian Cancer: Results From Combined Data Sets
Other, Other, Publications Archival vs Fresh Tumor Samples for Assessing the Gene Expression of NaPi2b and Immune-Related Genes in the Phase 1 Study of Upifitamab Rilsodotin (UpRi) in Platinum-Resistant Ovarian Cancer
